Several groups tested the hypothesis that upregulation of endogenous laminin-α1 or exogenous treatment with laminin-111 protein can alleviate disease progression in mouse models of DMD and LAMA2-CMD (Table 1). The gene discussed is LAMA2; the disease is congenital muscular dystrophy.